Lumera Corporation and Harvard Medical School to Collaborate on New Protein Biochip
Lumera Corporation recently announced it has entered into a collaborative agreement to develop a protein biochip with Harvard Medical School (HMS) and the Harvard Institute of Proteomics, a division of HMS. Lumera and HMS will develop a next generation silicon chip substrate that combines Lumera’s NanoCapture™ technology with HMS’s NAPPA™ methodology (nucleic acid programmable protein arrays). The resultant 10,000-spot very high density protein arrays is expected to radically increase the speed of drug discovery and life sciences research.
Using available research methods and materials, array densities of up to approximately 800 spots are possible. With the proprietary Lumera array, scientists and researchers will soon be able to analyze high-throughput expression of more than 10,000 discrete proteins in biologically-active arrays constructed from available cDNA libraries.
Lumera and HMS will jointly share rights to all developed intellectual property.